This company has been acquired
Radius Health (RDUS) Stock Overview
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
RDUS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Radius Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.10 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$4.97 |
| Beta | 0.52 |
| 1 Month Change | -0.39% |
| 3 Month Change | 78.76% |
| 1 Year Change | -27.08% |
| 3 Year Change | -55.21% |
| 5 Year Change | -71.49% |
| Change since IPO | 26.09% |
Recent News & Updates
Radius Recycling's Surge Justifies A Reevaluation
Mar 14Radius Recycling Will Benefit From Steel Tariffs
Feb 25Radius Recycling Stays In The Scrap Pile
Jul 16Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Jun 03Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Recent updates
Radius Recycling's Surge Justifies A Reevaluation
Mar 14Radius Recycling Will Benefit From Steel Tariffs
Feb 25Radius Recycling Stays In The Scrap Pile
Jul 16Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Jun 03Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Shareholder Returns
| RDUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.1% | -0.8% | 2.0% |
| 1Y | -27.1% | 2.9% | 18.7% |
Return vs Industry: RDUS underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: RDUS underperformed the US Market which returned -11.6% over the past year.
Price Volatility
| RDUS volatility | |
|---|---|
| RDUS Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RDUS's share price has been volatile over the past 3 months.
Volatility Over Time: RDUS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 293 | G. Martin | radiuspharm.com |
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome.
Radius Health, Inc. Fundamentals Summary
| RDUS fundamental statistics | |
|---|---|
| Market cap | US$480.77m |
| Earnings (TTM) | -US$68.63m |
| Revenue (TTM) | US$223.36m |
Is RDUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDUS income statement (TTM) | |
|---|---|
| Revenue | US$223.36m |
| Cost of Revenue | US$19.47m |
| Gross Profit | US$203.89m |
| Other Expenses | US$272.52m |
| Earnings | -US$68.63m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 91.28% |
| Net Profit Margin | -30.72% |
| Debt/Equity Ratio | -124.2% |
How did RDUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/11 17:21 |
| End of Day Share Price | 2022/08/11 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Radius Health, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| John Newman | Canaccord Genuity |
| Mara Goldstein | Cantor Fitzgerald & Co. |